Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Octreotide MeSH Descriptor Data 2025


MeSH Heading
Octreotide
Tree Number(s)
D04.345.566.650
D12.644.641.650
Unique ID
D015282
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D015282
Scope Note
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
Entry Term(s)
Compound 201-995
Octreotide Acetate
Octreotide Acetate Salt
SAN 201-995
SM 201-995
SMS 201-995
Sandostatin
Sandostatine
Sandoz 201-995
Pharm Action
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Registry Numbers
RWM8CCW8GP
0
75R0U2568I
Related Numbers
75R0U2568I
83150-76-9
CAS Type 1 Name
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-
Previous Indexing
Antineoplastic Agents (1982-1988)
Somatostatin/analogs & derivatives (1982-1988)
Public MeSH Note
89
History Note
89
Date Established
1989/01/01
Date of Entry
1988/05/23
Revision Date
2013/07/08
Octreotide Preferred
Sandostatine Narrower
Octreotide Acetate Narrower
SMS 201-995 Narrower
page delivered in 0.13s